Welcome guest, Sign in

Home


Joy Y. Feng

Education

Ph.D. in Medicinal Chemistry, University of Florida, College of Pharmacy, 1996

Current position

Senior Research Scientist II, Gilead Sciences, Foster City, CA (2003-present)

Publications (since 2005)

  1. Gaur, V., Vyas, R., Fowler, J. D., Efthimiopoulos, G., Feng, J. Y. and Suo, Z. (2014). Structural and kinetic insights into binding and incorporation of L-nucleotide analogs by a Y-family DNA polymerase. Nucleic Acids Res 42(15): 9984-9995.
  2. Mish, M. R., Cho, A., Kirschberg, T., Xu, J., Zonte, C. S., Fenaux, M., Park, Y., Babusis, D., Feng, J. Y., Ray, A. S. and Kim, C. U. (2014). Preparation and biological evaluation of 1'-cyano-2'-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors. Bioorg Med Chem Lett 24(14): 3092-3095.
  3. Feng, J. Y., Cheng, G., Perry, J., Barauskas, O., Xu, Y., Fenaux, M., Eng, S., Tirunagari, N., Peng, B., Yu, M., Tian, Y., Lee, Y. J., Stepan, G., Lagpacan, L. L., Jin, D., Hung, M., Ku, K. S., Han, B., Kitrinos, K., Perron, M., Birkus, G., Wong, K. A., Zhong, W., Kim, C. U., Carey, A., Cho, A. and Ray, A. S. (2014). Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother 58(4): 1930-1942.
  4. Kulkarni, R., Feng, J. Y., Miller, M. D. and White, K. L. (2014). Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir. Antiviral Res 101: 131-135.
  5. Parrish, J. P., Lee, S. K., Boojamra, C. G., Hui, H., Babusis, D., Brown, B., Shih, I. H., Feng, J. Y., Ray, A. S. and Mackman, R. L. (2013). Evaluation of 2'-alpha-fluorine modified nucleoside phosphonates as potential inhibitors of HCV polymerase. Bioorg Med Chem Lett 23(11): 3354-3357.
  6. Cho, A., Zhang, L., Xu, J., Lee, R., Butler, T., Metobo, S., Aktoudianakis, V., Lew, W., Ye, H., Clarke, M., Doerffler, E., Byun, D., Wang, T., Babusis, D., Carey, A. C., German, P., Sauer, D., Zhong, W., Rossi, S., Fenaux, M., McHutchison, J. G., Perry, J., Feng, J., Ray, A. S. and Kim, C. U. (2014). Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. J Med Chem 57(5): 1812-1825.
  7. Arnold, J. J., Sharma, S. D., Feng, J. Y., Ray, A. S., Smidansky, E. D., Kireeva, M. L., Cho, A., Perry, J., Vela, J. E., Park, Y., Xu, Y., Tian, Y., Babusis, D., Barauskus, O., Peterson, B. R., Gnatt, A., Kashlev, M., Zhong, W. and Cameron, C. E. (2012). Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog 8(11): e1003030.
  8. Cho, A., Saunders, O. L., Butler, T., Zhang, L., Xu, J., Vela, J. E., Feng, J. Y., Ray, A. S. and Kim, C. U. (2012). Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg Med Chem Lett 22(8): 2705-2707.
  9. Das, K., Bandwar, R. P., White, K. L., Feng, J. Y., Sarafianos, S. G., Tuske, S., Tu, X., Clark, A. D., Jr., Boyer, P. L., Hou, X., Gaffney, B. L., Jones, R. A., Miller, M. D., Hughes, S. H. and Arnold, E. (2009). Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem 284(50): 35092-35100.
  10. Koch, K., Chen, Y., Feng, J. Y., Borroto-Esoda, K., Deville-Bonne, D., Gallois-Montbrun, S., Janin, J. and Morera, S. (2009). Nucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivatives. Nucleos Nucleot Nucl 28(8): 776-792.
  11. Paulson, M. S., Yang, H., Shih, I. H., Feng, J. Y., Mabery, E. M., Robinson, M. F., Zhong, W. and Delaney, W. E. t. (2009). Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus. Antiviral Res 83(2): 135-142. 
  12. Feng, J. Y., Ly, J. K., Myrick, F., Goodman, D., White, K. L., Svarovskaia, E. S., Borroto-Esoda, K. and Miller, M. D. (2009). The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 6: 44.
  13. Svarovskaia, E. S., Feng, J. Y., Margot, N. A., Myrick, F., Goodman, D., Ly, J. K., White, K. L., Kutty, N., Wang, R., Borroto-Esoda, K. and Miller, M. D. (2008). The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J Acquir Immune Defic Syndr 48(4): 428-436.
  14. Ray, A. S., Feng, J. Y., Murakami, E., Chu, C. K., Schinazi, R. F. and Anderson, K. S. (2007). Interaction of 2'-deoxyguanosine triphosphate analogue inhibitors of HIV reverse transcriptase with human mitochondrial DNA polymerase gamma. Antivir Chem Chemother 18(1): 25-33. 
  15. White, K. L., Chen, J. M., Feng, J. Y., Margot, N. A., Ly, J. K., Ray, A. S., Macarthur, H. L., McDermott, M. J., Swaminathan, S. and Miller, M. D. (2006). The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther 11(2): 155-163.
  16. Feng, J. Y., Myrick, F. T., Margot, N. A., Mulamba, G. B., Rimsky, L., Borroto-Esoda, K., Selmi, B. and Canard, B. (2006). Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine. Nucleos Nucleot Nucl 25(1): 89-107.
  17. Feng, J. Y., Myrick, F., Selmi, B., Deval, J., Canard, B. and Borroto-Esoda, K. (2005). Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine. Antiviral Res 66(2-3): 153-158.

Book chapter

  1. Feng, J. Y. and Furman, P. A. (2005) Chapter 13, Other Drug Applications. In: Vaghefi, M. (ed). Nucleoside Triphosphates and their Analogs: Chemistry, Biotechnology, and Biological Applications. Taylor & Francis, pp 343-372.
Protocols by Joy Y. Feng
  1. Determination of Mitochondrial DNA Upon Drug Treatment
  2. Mitochondrial Biogenesis Assay after 5-day Treatment in PC-3 Cells